Quadrivalent influenza vaccine in the United States.
New strategies to improve influenza vaccines are ongoing. With the recent development of new vaccine formulations, such improvement are have begun to materialize in formulations available to providers and their patients. One of the newest strategies developed has been to broaden the composition of the current influenza vaccine formulations from trivalent products to quadrivalent products. To date, three manufacturers have developed and tested four vaccine formulations for safety and immunogenicity. The growing availability of quadrivalent influenza vaccines is now a well-recognized advance among the growing opportunities to improve influenza prevention.
State University of New York; Upstate Medical University; Syracuse, NY USA.
Manika
M
Suryadevara
Joseph B
JB
Domachowske
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002626:Chemistry, Pharmaceutical; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D014481:United States; D014611:Vaccination / Q000009:adverse effects / Q000379:methods*; D055815:Young Adult
D007252:Influenza Vaccines
influenza virus; quadrivalent influenza vaccine